Chemotherapy consisting of epirubicin, cisplatin, and etoposide followed by irradiation in stage III non-small cell lung cancer and chemotherapy alone in stage IV non-small cell lung cancer.
Twenty-eight patients with stage III non-small cell lung cancer were treated with the sequential administration of combination chemotherapy consisting of epirubicin, cisplatin, and etoposide and of irradiation. The response rate was 57% including 15% complete responses. The median survival time was 11 months. Eighteen patients with stage IV disease received the same chemotherapy. The response rate was 55% including 11% complete responses, but the median survival time was only 5 months. It is concluded that this protocol is as active as the combination of doxorubicin, etoposide, and cisplatin, but probably less toxic.
Wils
J
J
Department of Internal Medicine, Laurentius Hospital, Roermond, The Netherlands.
Utama
I
I
Smeets
J
J
D000206:Actuarial Analysis; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000532:radiotherapy; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D015251:Epirubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging
D015251:Epirubicin; D005047:Etoposide; D002945:Cisplatin